- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06793397
Een fase 3 -studie om CYB003 te beoordelen bij de belangrijkste depressieve stoornis (EMBRACE)
Een werkzaamheid en veiligheid, fase III, multi-center, dubbelblinde, gerandomiseerde gecontroleerde studie waarin 2 actieve doses Cyb003 en placebo worden vergeleken bij in aanmerking komende deelnemers met ernstige depressieve stoornis
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Clinical Development
- Telefoonnummer: 877-361-4003
- E-mail: clinicaltrialsinfo@cybin.com
Studie Locaties
-
-
New South Wales
-
Camperdown, New South Wales, Australië, 2050
- Werving
- Royal Prince Alfred Hospital
-
Hoofdonderzoeker:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australië, 4558
- Werving
- Thompson Brain & Mind Healthcare (TBMH)
-
Hoofdonderzoeker:
- Adem Can
-
Contact:
- Megan Dutton
- Telefoonnummer: +61 4160 40977
- E-mail: mdutton@tbmh.org.au
-
Contact:
- Kristy Smyth
- Telefoonnummer: +61 4324 41227
- E-mail: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australië, 3004
- Werving
- Ramsay Clinic
-
Hoofdonderzoeker:
- Malcolm Hopwood
-
Contact:
- Melanie Hurley
- Telefoonnummer: 03 9279 3569
- E-mail: research.arc@ramsayhealth.com.au
-
Contact:
- Grace Monigatti
- Telefoonnummer: 03 9279 3569
- E-mail: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australië, 3053
- Werving
- Neurocentrix Research
-
Hoofdonderzoeker:
- David Barton
-
Contact:
- Mai-Anh Bui
- Telefoonnummer: +61 3 9546 0009
- E-mail: mai@neurocentrix.com.au
-
Contact:
- Gabriela Gonzalez
- Telefoonnummer: +61 3 9959 8375
- E-mail: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australië, 3168
- Werving
- Monash University - Notting Hill
-
Contact:
- Olivia Lavalette
- Telefoonnummer: 0426359494
- E-mail: olivia.lavalette@monash.edu
-
Hoofdonderzoeker:
- Paul Liknaitzky
-
-
-
-
-
Berlin, Duitsland, 10117
- Nog niet aan het werven
- Charité Universitaetsmedizin Berlin
-
Hoofdonderzoeker:
- Michael Koslowski
-
Contact:
- Telefoonnummer: +49 30 450 617734
- E-mail: psychedelika-studien@charite.de
-
Frankfurt am Main, Duitsland, 60528
- Nog niet aan het werven
- University Hospital Frankfurt
-
Hoofdonderzoeker:
- Andreas Reif
-
Contact:
- Tanja Scharf
- Telefoonnummer: +49 69 6301 86078
- E-mail: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Duitsland, 68159
- Nog niet aan het werven
- Central Institute of Mental Health
-
Contact:
- Karin Bopp
- Telefoonnummer: 3016 +49 621 1703 3163
- E-mail: Karin.bopp@zi-mannheim.de
-
Hoofdonderzoeker:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Duitsland, 66421
- Nog niet aan het werven
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Hoofdonderzoeker:
- Matthias Riemenschneider
-
Contact:
- Christine Geiger
- Telefoonnummer: +49 6841 1624227
- E-mail: christine.geiger@uks.eu
-
Contact:
- Aline Freer
- Telefoonnummer: +49 6841 1614219
- E-mail: aline.freer@uks.eu
-
-
-
-
-
Athens, Griekenland, 12462
- Werving
- Attikon University Hospital
-
Hoofdonderzoeker:
- Nikolaos Smyrnis
-
Contact:
- Thomas Karantinos
- Telefoonnummer: +30697466610
- E-mail: tkarantinos@gmail.com
-
Athens, Griekenland, 11528
- Werving
- Eginitio Hospital
-
Hoofdonderzoeker:
- Nikos Stefanis
-
Contact:
- Adam Adamopoulos
- Telefoonnummer: +30 6976032181
- E-mail: adam_adamopoulos@yahoo.com
-
Thessaloniki, Griekenland, 56404
- Werving
- Papageorgiou General Hospital
-
Hoofdonderzoeker:
- Georgios Papazisis
-
Contact:
- Ogla Vampertzi
- Telefoonnummer: +306973852659
- E-mail: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Ierland, D24 WK80
- Werving
- Sheaf House - Tallaght Adult Mental Health Service
-
Hoofdonderzoeker:
- John Kelly
-
Contact:
- Ann Connolly
- Telefoonnummer: +353 8616 79619
- E-mail: aconnolly@crp.healthcare
-
Galway, Ierland, H91 VE03
- Werving
- La Nua Day Hospital Mental Health Centre
-
Contact:
- Prathyusha Nedunuru
- Telefoonnummer: +353 874283750
- E-mail: pnedunuru@crp.healthcare
-
Hoofdonderzoeker:
- Shane McInerney
-
-
-
-
-
Bialystok, Polen, 15-272
- Ingetrokken
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Polen, 85-133
- Werving
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Contact:
- Franciszek Lauchut
- Telefoonnummer: +48 790 219 501
- E-mail: f.lachut@pro-mente.pl
-
Hoofdonderzoeker:
- Katarzyna Lachut
-
Gdansk, Polen, 80-546
- Werving
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Contact:
- Monika Drzewiecka
- Telefoonnummer: +48 508-348-938
- E-mail: m.drzewiecka@pihouse.pl
-
Hoofdonderzoeker:
- Hanna Badzio-Jagiello
-
Gdansk, Polen, 80-214
- Nog niet aan het werven
- UCK
-
Hoofdonderzoeker:
- Wieslaw Jerzy Cubala
-
Contact:
- Natalia Sudol
- Telefoonnummer: +48 669 439 740
- E-mail: nat.sudol13@gmail.com
-
Warsaw, Polen, 02-957
- Nog niet aan het werven
- Department of Pharmacology and Physiology of CNS
-
Hoofdonderzoeker:
- Justyna Holka-Pokorska
-
Warsaw, Polen, 02-172
- Werving
- MTZ Clinical Research Powered by Pratia
-
Hoofdonderzoeker:
- Monika Gawlowicz
-
-
-
-
-
Prague, Tsjechië
- Nog niet aan het werven
- Institute of neuropsychiatric Care (INEP)
-
Hoofdonderzoeker:
- Alexander Nawka
-
Contact:
- Telefoonnummer: +420 222 201 020
- E-mail: info@inep.cz
-
Prague, Tsjechië
- Nog niet aan het werven
- Psyon s.r.o.
-
Hoofdonderzoeker:
- Tomas Palenicek
-
Contact:
- Telefoonnummer: +420 774 401 161
- E-mail: info@psyon.cz
-
Předměstí, Tsjechië
- Nog niet aan het werven
- A-SHINE s.r.o.
-
Hoofdonderzoeker:
- Lubos Janu
-
Contact:
- Blanka Vopelková
- Telefoonnummer: +490 777 732 244
- E-mail: blanka.vopelkova@seznam.cz
-
-
-
-
-
Cambridge, Verenigd Koninkrijk, CB1 2EU
- Werving
- Cambridge University Hospital NHS
-
Hoofdonderzoeker:
- Liliana Galindo
-
Contact:
- Tracy Assari
- Telefoonnummer: +44 1223 219751
- E-mail: t.assari@nhs.net
-
Contact:
- Emma Tudor
- Telefoonnummer: +44 1223 219751
- E-mail: Emma.tudor@cpft.nhs
-
Doncaster, Verenigd Koninkrijk, DN4 8QN
- Werving
- Clerkenwell Health - Doncaster
-
Hoofdonderzoeker:
- Paul Morrison
-
Contact:
- Celia Creaghan
- Telefoonnummer: +44 7849 640886
- E-mail: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Verenigd Koninkrijk, EH16 4TJ
- Nog niet aan het werven
- NHS Research Scotland
-
Hoofdonderzoeker:
- Donald MacIntyre
-
Contact:
- Carrie Wardhaugh
- Telefoonnummer: +44 1315375867
- E-mail: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Verenigd Koninkrijk, G51 4TF
- Nog niet aan het werven
- Queen Elizabeth University Hospital
-
Hoofdonderzoeker:
- Maytal Wolfe
-
Contact:
- Rebecca Baird
- E-mail: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Verenigd Koninkrijk, L7 8XP
- Nog niet aan het werven
- Royal Liverpool Hospital
-
Contact:
- Rachel Crick
- Telefoonnummer: +44730 861 3597
- E-mail: Rachel.Crick@merseycare.nhs.uk
-
Hoofdonderzoeker:
- Fabian Devlin
-
London, Verenigd Koninkrijk, EC2Y 8EA
- Werving
- St Pancras Clinical Research
-
Hoofdonderzoeker:
- Martin Johnson
-
Contact:
- Participant Engagement Team
- Telefoonnummer: +44 20 38651142
- E-mail: studyinformation@stpancrasclinical.com
-
London, Verenigd Koninkrijk, W1U 6RP
- Werving
- Clerkenwell Health - Baker Street
-
Hoofdonderzoeker:
- Alishah Suleman
-
Contact:
- Takunda Gwenhure
- Telefoonnummer: +44 2038974867
- E-mail: tgwenhure@clerkenwellhealth.com
-
Contact:
- Victor Jardim
- Telefoonnummer: +44 2038974867
- E-mail: vjardim@clerkenwellhealth.com
-
London, Verenigd Koninkrijk, W1G9 RU
- Werving
- Re:Cognition Health
-
Hoofdonderzoeker:
- Dimitrios Paschos
-
Contact:
- Telefoonnummer: +44-0800-802-1030
-
London, Verenigd Koninkrijk, SE5 9RS
- Werving
- King's College London
-
Contact:
- Catheine Bird
- E-mail: catherine.bird@kcl.ac.uk
-
Contact:
- Paige Seath
- E-mail: paige.seath@kcl.ac.uk
-
Hoofdonderzoeker:
- James Rucker
-
London, Verenigd Koninkrijk, W1G 8DR
- Ingetrokken
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Verenigd Koninkrijk, NE4 5PL
- Werving
- Edwardson Building - Campus for Ageing and Vitality
-
Contact:
- Victoria Wilson
- Telefoonnummer: +44 191 246 8647
- E-mail: victoria.wilson3@cntw.nhs.uk
-
Contact:
- Rebecca Woodhouse
- E-mail: Rebecca.Woodhouse@cntw.nhs.uk
-
Hoofdonderzoeker:
- Mourad Wahba
-
Reading, Verenigd Koninkrijk, RG7 8PA
- Werving
- Ascend Clinical Research
-
Hoofdonderzoeker:
- Pamela Walters
-
Contact:
- Alexandra Diaz
- Telefoonnummer: +44 118 3045905
- E-mail: adiaz@ascendclinical-research.com
-
Sheffield, Verenigd Koninkrijk, S4 7QQ
- Werving
- Sheffield Health and Social Care NHS Foundation Trust
-
Hoofdonderzoeker:
- William Gann
-
Contact:
- Mishell Cunningham
- Telefoonnummer: +44 114 271 6731
- E-mail: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35209
- Werving
- UAB Psychiatry and Behavioral Neurology
-
Contact:
- Seher Premani
- Telefoonnummer: 205-996-1198
- E-mail: spremani@uab.edu
-
Hoofdonderzoeker:
- Peter Hendricks
-
Contact:
- Maggie Gossage
- E-mail: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Verenigde Staten, 85234
- Werving
- Lighthouse Psychiatry
-
Contact:
- Chung Trinh
- Telefoonnummer: 435-268-5800
- E-mail: ctrinh@neosciclinicalresearch.com
-
Hoofdonderzoeker:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72204
- Ingetrokken
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, Verenigde Staten, 91206
- Werving
- Behavioral Research Specialists, LLC
-
Hoofdonderzoeker:
- Jesse Carr
-
Contact:
- Laisha Uribe
- Telefoonnummer: 888-255-5798
- E-mail: laisha@brstrials.com
-
Imperial, California, Verenigde Staten, 92251
- Ingetrokken
- Sun Valley Research Center
-
Los Angeles, California, Verenigde Staten, 90025
- Werving
- CalNeuro Research Group
-
Hoofdonderzoeker:
- Alexander Bystritsky
-
Contact:
- Telefoonnummer: 310-208-7144
- E-mail: info@calneuroresearch.com
-
Los Angeles, California, Verenigde Staten, 90025
- Werving
- Lipov Medical Group
-
Contact:
- Brittany Juhlmann
- Telefoonnummer: 262-352-8835
- E-mail: brittany.juhlmann@stellacenter.com
-
Hoofdonderzoeker:
- Jacob Moussai
-
Orange, California, Verenigde Staten, 92868
- Werving
- NRC Research Institute
-
Contact:
- Christian Ortiz
- Telefoonnummer: 714-289-1100
- E-mail: cortiz@nrcresearch.com
-
Hoofdonderzoeker:
- Daniel Chueh
-
Orange, California, Verenigde Staten, 92866
- Werving
- ATP Clinical Research
-
Hoofdonderzoeker:
- Gustavo Alva
-
Contact:
- Sarah Perkins
- Telefoonnummer: 949-354-5353
- E-mail: sarahp@pnsoc.com
-
San Juan Capistrano, California, Verenigde Staten, 92675
- Werving
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Hoofdonderzoeker:
- Neelima Kunam
-
Contact:
- Telefoonnummer: 909-955-5865
- E-mail: research@inlandpsych.com
-
Santa Monica, California, Verenigde Staten, 90404
- Werving
- Psychedelic Science Institute
-
Hoofdonderzoeker:
- Keith Heinzerling
-
Contact:
- Telefoonnummer: 213-973-7512
- E-mail: trialadmin@psychedelicsci.com
-
Stanford, California, Verenigde Staten, 94305
- Ingetrokken
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06511
- Werving
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Hoofdonderzoeker:
- Ben Kelmendi
-
Contact:
- Daidre Chamberlain
- Telefoonnummer: 203-693-1591
- E-mail: enact@yale.edu
-
Contact:
- Terrence Ching
- Telefoonnummer: 502-612-1127
- E-mail: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32256
- Werving
- CNS Healthcare
-
Contact:
- Telefoonnummer: 904-281-5757
-
Hoofdonderzoeker:
- John Mark Joyce
-
Maitland, Florida, Verenigde Staten, 32751
- Werving
- Accel Research Sites - Maitland
-
Contact:
- Telefoonnummer: 407-644-1165
-
Hoofdonderzoeker:
- Andrea Marrafino
-
Naples, Florida, Verenigde Staten, 34105
- Werving
- Aqualane Clinical Research
-
Hoofdonderzoeker:
- Matthew Baker
-
Contact:
- Rachel Novella
- Telefoonnummer: 239-529-6780
- E-mail: Rachel@Aqualaneresearch.com
-
Tampa, Florida, Verenigde Staten, 33634
- Werving
- K2 Medical Research Tampa
-
Hoofdonderzoeker:
- Kelley Wilson
-
Contact:
- Jessica Myers
- Telefoonnummer: 352-500-5252
- E-mail: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Ingetrokken
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, Verenigde Staten, 30060
- Werving
- Psych Atlanta
-
Hoofdonderzoeker:
- Michael Banov
-
Contact:
- Telefoonnummer: 770-422-2846
- E-mail: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60612
- Werving
- Rush University
-
Hoofdonderzoeker:
- Joshua Eloge
-
Contact:
- Stephanie Gutierrez
- Telefoonnummer: 312-942-8995
- E-mail: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, Verenigde Staten, 70006
- Ingetrokken
- Tandem Clinical Research
-
New Orleans, Louisiana, Verenigde Staten, 70115
- Werving
- Atlas Psychiatry
-
Contact:
- Milton Boresoff
- Telefoonnummer: 504-899-1682
- E-mail: m.boresoff@atlaspsychiatry.com
-
Hoofdonderzoeker:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21224
- Ingetrokken
- Johns Hopkins Medicine
-
Rockville, Maryland, Verenigde Staten, 20850
- Nog niet aan het werven
- Sunstone Medical, PC
-
Contact:
- Manish Agrawal, MD
- Telefoonnummer: 301-750-3401
- E-mail: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02116
- Werving
- Adams Clinical Boston
-
Hoofdonderzoeker:
- Darin Dougherty
-
Contact:
- Participant Navigators
- Telefoonnummer: 617-404-4714
- E-mail: info@adamsclinical.com
-
Watertown, Massachusetts, Verenigde Staten, 02472
- Werving
- Adams Clinical Watertown
-
Hoofdonderzoeker:
- Stephanie Ellickson
-
Contact:
- Participant Navigators
- Telefoonnummer: 617-404-4714
- E-mail: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, Verenigde Staten, 55347
- Werving
- Institute for Integrative Therapies
-
Hoofdonderzoeker:
- Manoj Doss
-
Contact:
- Sena Ostwalt
- Telefoonnummer: 6512808774
- E-mail: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, Verenigde Staten, 55427
- Nog niet aan het werven
- The Remedy Mental Health
-
Contact:
- Emmanuel Arhin
- Telefoonnummer: (651) 382-9518
- E-mail: emmanuel.arhin@theremedymn.com
-
Hoofdonderzoeker:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89119
- Werving
- Redbird Research, LLC
-
Hoofdonderzoeker:
- Jelena Kunovac
-
Contact:
- Telefoonnummer: 702-577-2000
- E-mail: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, Verenigde Staten, 08755
- Werving
- Bio Behavioral Health
-
Contact:
- Jessica Sutton
- Telefoonnummer: 732-244-2299
- E-mail: jessica@bbhnj.com
-
Hoofdonderzoeker:
- Ashok Patel
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Nog niet aan het werven
- New York State Psychiatric Institute
-
Hoofdonderzoeker:
- Natalie Gukasyan
-
Contact:
- Alexandra Mackay
- Telefoonnummer: 212-342-1424
- E-mail: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, Verenigde Staten, 10029
- Werving
- Adams Clinical Harlem
-
Contact:
- Participant Navigators
- Telefoonnummer: 917-454-3746
- E-mail: info@adamsclinical.com
-
Hoofdonderzoeker:
- Wesley Gregory
-
The Bronx, New York, Verenigde Staten, 10461
- Werving
- Adams Clinical Bronx
-
Hoofdonderzoeker:
- Shama Farooq
-
Contact:
- Participant Navigators
- Telefoonnummer: 917-454-3746
- E-mail: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73112
- Ingetrokken
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Werving
- Adams Clinical Philadelphia
-
Hoofdonderzoeker:
- Cassie Blanchard
-
Contact:
- Participant Navigators
- Telefoonnummer: 267-376-0266
- E-mail: info@adamsclinical.com
-
Philadelphia, Pennsylvania, Verenigde Staten, 19462
- Werving
- Flourish Research Philadelphia
-
Hoofdonderzoeker:
- Rachna Saralkar
-
Contact:
- Telefoonnummer: 215-614-5606
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78737
- Ingetrokken
- Austin Clinical Trial Partners
-
DeSoto, Texas, Verenigde Staten, 75115
- Werving
- Adams Clinical Dallas
-
Hoofdonderzoeker:
- Rajinder Shiwach
-
Contact:
- Participant Navigators
- Telefoonnummer: 469-379-2494
- E-mail: info@adamsclinical.com
-
Fort Worth, Texas, Verenigde Staten, 76104
- Ingetrokken
- North Texas Clinical Trials
-
Houston, Texas, Verenigde Staten, 77046
- Werving
- Brain Health Consultants and TMS Center
-
Hoofdonderzoeker:
- Lauren Marangell
-
Contact:
- Telefoonnummer: 713-489-5000
- E-mail: info@brainhealthconsultants.com
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- Flourish Research San Antonio
-
Hoofdonderzoeker:
- Parke Hedges
-
Contact:
- Xavier Martinez
- Telefoonnummer: 237 210-949-0122
- E-mail: xmartinez@flourishresearch.com
-
Contact:
- Andrea Gomez
- Telefoonnummer: 122 210-949-0122
- E-mail: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, Verenigde Staten, 98201
- Nog niet aan het werven
- Core Clinical Research
-
Contact:
- Maria Golescu
- Telefoonnummer: 425-443-9551
- E-mail: maria.golescu@ccrtrial.com
-
Hoofdonderzoeker:
- James Knutson
-
Seattle, Washington, Verenigde Staten, 98104
- Werving
- Seattle Neuropsychiatric Treatment Center
-
Hoofdonderzoeker:
- Rebecca Allen
-
Contact:
- Telefoonnummer: 5 206-467-6300
- E-mail: research@seattlentc.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Experimenteel: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Placebo-vergelijker: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Tijdsspanne: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Tijdsspanne: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Tijdsspanne: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Tijdsspanne: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Tijdsspanne: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Felix Mazer, Cybin IRL Limited
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CYB003-003
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .